Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Metadata
Title
Plasma and CSF pharmacokinetics of ganciclovir in nonhuman primates
Authors
Baruti M. Serabe
Daryl J. Murry
Robert Dauser
Jed Nuchtern
John Durfee
Leticia McGuffey
Stacey Berg
Susan M. Blaney
Publication date
01-03-1999
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 5/1999
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s002800050916

Other articles of this Issue 5/1999

Cancer Chemotherapy and Pharmacology 5/1999 Go to the issue

ORIGINAL ARTICLE

In vitro interactions of a new derivative of spicamycin, KRN5500, and other anticancer drugs using a three-dimensional model

ORIGINAL ARTICLE

A comparative study of administration methods of granisetron injection used to treat nausea/vomiting induced by cancer chemotherapy without cisplatin in tumors of hematopoietic organs

ORIGINAL ARTICLE

Comparative brain tissue distribution of camptothecin and topotecan in the rat

ORIGINAL ARTICLE

A pilot study of melphalan, tumor necrosis factor-α and 41.8 °C whole-body hyperthermia

ORIGINAL ARTICLE

Sonodynamically induced effect of rose bengal on isolated sarcoma 180 cells

ORIGINAL ARTICLE

A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits